The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Clinical trial NCT06520345 · RECRUITING

Trial details

NCT number: NCT06520345
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Metastatic Castration-resistant Prostate Cancer

Start date: 2024-07-26
Primary completion: 2027-12-01
Enrollment: 520

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.